Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of its first full-length synthetic genome for the highly infectious Delta variant of the SARS-CoV-2 virus (B.1.617 lineage). The genome was synthesized and constructed using Codex DNA’s BioXp™ 3250 system, its fully automated synthetic biology benchtop workstation for rapid, accurate, and reproducible writing of DNA and mRNA.
